Spine fusion by gene therapy.

Area of Science:

• Orthopedics
• Regenerative Medicine
• Biotechnology

Background:

• Spine fusion procedures are common, yet up to 35% fail to achieve solid bony arthrodesis, presenting a significant clinical challenge.
• Current augmentation methods using osteoinductive proteins have limitations, including cost and carrier material issues.
• Gene therapy is emerging as a potential alternative strategy to improve bone formation and fusion rates.

Purpose of the Study:

• To review the current state of local gene therapy for bone formation.
• To identify critical factors for developing successful gene therapy programs for spine fusion.
• To highlight challenges and considerations for clinical translation.

Main Methods:

• Review of existing literature on gene therapy for bone regeneration.
• Analysis of critical parameters for gene therapy development: gene selection, delivery vectors, dosage, and carrier materials.
• Discussion of in vitro and in vivo testing strategies.

Main Results:

• Recombinant human bone morphogenetic protein-2 is FDA-approved for lumbar interbody fusion, but limitations persist.
• Gene therapy requires careful selection of osteoinductive genes and appropriate delivery vectors.
• Optimization of effective dose, transduction time, gene transfer method, and carrier scaffolds is crucial.
• Robust in vitro and in vivo testing strategies are necessary for successful human trials.

Conclusions:

• Local gene therapy presents a viable alternative to current bone graft augmentation for spine fusion.
• Successful gene therapy development hinges on strategic choices regarding gene, vector, dose, and delivery system.
• Further research and rigorous testing are essential to advance gene therapy for bone healing applications.